Vous avez cherché: pid (Anglais - Croate)

pid
pid

invalid pid
neispravan pid

pid: %1 (%2)
id procesa:% 1 (% 2) authorization scope

pid of crashed program
pid programa koji se srušio

pid of the application to terminate
pid aplikacije potreban za prekid

single shot pid: %1 (%2)
jedan id procesa:% 1 (% 2) authorization scope; pid is process id

only try to reuse kate instance with this pid
pokušaj samo ponovo upotrijebiti kate s ovim pid- om

replacement therapy in primary immunodeficiency (pid)
nadomjesno liječenje kod primarne imunodeficijencije (pid)

replacement therapy in primary immunodeficiency (pid) syndromes
nadomjesna terapija kod sindroma primarne imunodeficijencije (pid)

methods and techniques of the particle identification ( pid ) .
metode i tehnike prepoznavanja čestica ( pid ) .

haemolysis has rarely been reported in patients given replacement therapy for pid.
hemoliza je rijetko uočena u bolesnika koji su primali nadomjesnu terapiju za pid.

in the pid extension study, 55 patients were enrolled and treated with privigen.
u nastavku ispitivanja pid-a bilo je uključeno 55 bolesnika koji su se liječili privigenom.

the pid pivotal study included a total of 80 patients aged between 3 and 69 years old.
u pivotalno ispitivanje pid-a uključeno je ukupno 80 bolesnika u dobi između 3 i 69 godina.

pharmacokinetic parameters for kiovig were determined in the two clinical studies in pid patients performed in europe and the us.
farmakokinetički parametri za kiovig utvrđeni su u dva klinička ispitivanja u bolesnika s pid-om provedenih u europi i sad-u.

in this study, the median half-life of privigen in pid patients was 36.6 days.
u ovom ispitivanju pokazano je da je medijan poluvijeka privigena u bolesnika s pid-om bio je 36,6 dana.

executable: %1 pid: %2 signal: %3 (%4)
izvršna datoteka:% 1 pid:% 2 signal:% 3 (% 4) @ action: button

these can be people who are born with a lack of antibodies (primary immunodeficiency syndrome, pid).
to mogu biti osobe koje su rođene s nedostatkom protutijela (sindrom primarne imunodeficijencije, pid).

efficacy and safety of hyqvia was assessed in a phase 3 study (160603) in 83 patients with pid.
djelotvornost i sigurnost lijeka hyqvia procijenjene su u ispitivanja faze 3 (160603) u 83 bolesnika s primarnom imunodeficijencijom.

in accordance with current guidelines for these medicines, hyqvia was investigated in one main study lasting over a year and involving 89 patients with pid who had already had treatment with human normal immunoglobulin for at least three months.
u skladu s trenutačnim smjernicama za te lijekove, lijek hyqvia ispitan je u jednom glavnom ispitivanju koje je trajalo godinu dana i obuhvatilo 89 bolesnika s pid-om koji su prethodno liječeni normalnim ljudskim imunoglobulinom barem tri mjeseca.

66 patients who completed the pivotal phase 3 study participated in an extension study (160902) for the evaluation of long-term safety, tolerability and efficacy of hyqvia in pid.
66 bolesnika koji su dovršili pivotalno ispitivanje faze 3 sudjelovalo je u nastavku ispitivanja (160902) radi procjene dugoročne sigurnosti, podnošljivosti i djelotvornosti lijeka hyqvia u primarnoj imunodeficijenciji.